Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + chemotherapy in first-line rare EGFR-mutant NSCLC (China, phase II)
CTR20212339Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212339.